Point-of-Care Coagulation Testing Market, By Test Type, By Technology, By End User, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

Point-of-Care Coagulation Testing Market size was valued at US$ 2,798.78 Million in 2024, expanding at a CAGR of 6.5% from 2025 to 2032.
Point-of-Care Coagulation Testing (POCCT) is revolutionizing healthcare by providing rapid, bedside blood clotting analysis that enables immediate, data-driven clinical decisions. The rising demand for fast, accurate coagulation diagnostics to personalize patient care in emergencies, surgeries, and bleeding disorders, supported by continuous innovation in connectivity, miniaturization, and AI integration is boosting market growth. Additionally, the market is witnessing a significant trend toward sophisticated viscoelastic testing that offers a comprehensive clot profile, improving trauma and surgical outcomes. A major growth opportunity lies in expanding home-based anticoagulant monitoring, empowering patients with chronic conditions to manage therapy conveniently. However, the market faces challenges in maintaining consistent and rigorous quality control when testing occurs outside centralized laboratory settings.

Point-of-Care Coagulation Testing Market- Market Dynamics

Growing prevalence of cardiovascular diseases
Globally, cardiovascular diseases such deep vein thrombosis, stroke, and atrial fibrillation are leading causes of death and morbidity. According to data published in July 2025, by World Health Organization (WHO), globally, cardiovascular diseases (CVDs) constitute the primary cause of mortality. About 19.8 million deaths worldwide in 2022 were attributed to CVDs, accounting for about 32% of the total number of deaths. Heart attacks and strokes were the cause of 85% of these fatalities. Moreover, CVDs were responsible for at least 38% of the 18 million premature deaths (those under 70) that occurred in 2021 as a result of noncommunicable diseases. Thus, in order to prevent potentially fatal side effects like bleeding or thrombosis, effective anticoagulation therapy necessitates routine monitoring of clotting parameters including Prothrombin Time (PT/INR) and Activated Clotting Time (ACT). However, centralized infrastructure and longer turnaround times associated with traditional laboratory testing may cause important treatment choices to be postponed. These obstacles are addressed by POC coagulation tests, which provide results in a matter of minutes at the patient's bedside, operating room, emergency hospital, or even their home. In addition to decreasing hospitalizations, this also improves patient adherence, particularly for long-term anticoagulant users.

Point-of-Care Coagulation Testing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.5% over the forecast period (2025-2032)
Based on Test Type segmentation, Prothrombin Time (PT/INR) Testing is predicted to show maximum market share in the year 2024
Based on Technology segmentation, Optical Technology is the leading Technology in 2024
Based on End User segmentation, Hospitals & Clinics is the leading Technology in 2024
On the basis of region, North America is the leading revenue generator in 2024

Point-of-Care Coagulation Testing Market- Segmentation Analysis:

The Global Point-of-Care Coagulation Testing Market is segmented on the basis of Test Type, Technology, End User, and Region.
The market is divided into five categories based on Test Type: Prothrombin Time (PT/INR) Testing, Activated Clotting Time (ACT) Testing, Activated Partial Thromboplastin Time (aPTT) Testing, Viscoelastic Testing (TEG, ROTEM, etc.), and Other Specialized Coagulation Tests. PT/INR monitors extrinsic pathway and warfarin, ACT guides high-dose heparin, aPTT checks intrinsic pathway and heparin, TEG/ROTEM analyze clot dynamics, others target specific disorders.
The market is divided into three categories based on Technology: Optical Technology, Mechanical Technology, and Electrochemical Technology. Optical technology measures light changes or patterns to detect clotting; mechanical technology assesses blood viscosity or movement to indicate clot formation; electrochemical technology detects electrical changes during coagulation.

Point-of-Care Coagulation Testing Market- Geographical Insights

North America dominates the market, driven by advanced healthcare infrastructure, widespread adoption, and a high prevalence of bleeding disorders. Additionally, North America exhibits widespread adoption of point-of-care coagulation testing due to the emphasis on rapid diagnosis, anticoagulant therapy management, and strong healthcare investments, among others. The UK and other Western nations are experiencing rapid growth in Europe as a result of encouraging government measures, increasing adoption of self-monitoring for chronic conditions, and demand for rapid, reliable monitoring, especially in anticoagulation therapy and surgery. Asia-Pacific is expected to witness the fastest growth, fueled by expanding healthcare access, mandates for cardiovascular clotting tests, and larger patient populations requiring rapid management of bleeding and thrombotic disorders. The Latin American point-of-care coagulation testing market is expanding steadily, owing to investment in rapid disease detection and effective management. Middle East and Africa, show rising demand, due to stroke management programs and an increasing focus on cartridge-based coagulation tests in specialty centers.

Point-of-Care Coagulation Testing Market- Competitive Landscape:

The point-of-care (POC) coagulation testing market is highly competitive and rapidly growing, driven by increasing demand for quick, accurate clotting assessments in clinical and home settings. Key players include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers, Sysmex Corporation, and Werfen, all focusing on expanding product portfolios through advanced technologies such as microfluidics, biosensors, and AI integration. These companies invest significantly in research, innovation, and strategic collaborations to enhance device accuracy, portability, and connectivity, enabling seamless integration with healthcare systems. For instance, in January 2022, F. Hoffmann-La Roche Ltd has announced the launch of the cobas pulse system in select countries with CE Mark approval. This new system represents Roche Diagnostics' latest generation of connected point-of-care solutions designed specifically for professional blood glucose management. Additionally, the market is characterized by a semi-consolidated structure, with a few dominant manufacturers holding substantial shares while numerous smaller companies compete in niche segments.

Recent Developments:

In July 2024, Werfen introduced GEM Premier 7000 with Intelligent Quality Management 3 (iQM3). The GEM Premier 7000 with iQM3 represented a breakthrough in blood gas testing, and offered hemolysis detection for first time at the point-of-care (POC).
In March 2023, Siemens Healthineers and Sysmex Corporation have established a global Original Equipment Manufacturer (OEM) agreement to supply hemostasis instruments and reagents. The strengthened collaboration leveraged their 25-year partnership to improve patient outcomes by advancing hemostasis testing technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL POINT-OF-CARE COAGULATION TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Siemens Healthineers
Abbott Laboratories
Sysmex Corporation
Werfen
Danaher Corporation
Medtronic
HemoSonics, LLC
Danaher Corporation
Trinity Biotech
F. Hoffmann-La Roche Ltd
Others

GLOBAL POINT-OF-CARE COAGULATION TESTING MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

Prothrombin Time (PT/INR) Testing
Activated Clotting Time (ACT) Testing
Activated Partial Thromboplastin Time (aPTT) Testing
Viscoelastic Testing (TEG, ROTEM, etc.)
Other Specialized Coagulation Tests

GLOBAL POINT-OF-CARE COAGULATION TESTING MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

Optical Technology
Mechanical Technology
Electrochemical Technology

GLOBAL POINT-OF-CARE COAGULATION TESTING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Ambulatory Surgical Centers (ASCs)
Diagnostic Laboratories
Home Care Settings
Others

GLOBAL POINT-OF-CARE COAGULATION TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more